RxDoctor Payments Data

Nancy Diaz-Pechar, MD

Neurology · Bethlehem, PANPI 1588837389

Payments from drug & device makers

$28,649in general payments, 2019–2025

Across 60 payments — averaging $477.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$25K
  • Boston Scientific$2K
  • Medtronic$1K
  • MDD US Operations, LLC$125
  • Acorda Therapeutics, Inc$100
  • AbbVie$50
  • plus $117 from 3 others
$580in research payments, 2019–2025

Across 1 payment — averaging $580.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$580

What the payments were for

  • Travel & lodging$2,50862%
  • Food & beverage$1,56538%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,649 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$221,074
Medicare patients
468
Services billed
18,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa104$162,616
IngrezzaValbenazine Tosylate17$125,219
NuplazidPimavanserin Tartrate23$113,456
GocovriAmantadine Hcl23$50,760
Austedo XrDeutetrabenazine11$42,487
InbrijaLevodopa11$38,556
Carbidopa-LevodopaCarbidopa/Levodopa723$30,740
NeuproRotigotine12$21,383
Rasagiline Mesylate120$17,536
Entacapone62$12,219
BotoxOnabotulinumtoxina11$11,345
Carbidopa-Levodopa ErCarbidopa/Levodopa177$10,045
Pramipexole ErPramipexole Di-Hcl18$8,905
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone21$8,839
OngentysOpicapone11$7,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$48$113,45623 claims
MDD US Operations, LLCGocovri$125$50,76023 claims
Acorda Therapeutics, IncInbrija$100$38,55611 claims
AbbVieBotox$50$11,34511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →